Login to Your Account

Clinic roundup

Friday, May 9, 2014
Aicuris AG, of Wuppertal, Germany, and Merck & Co. Inc., of Whitehouse Station, N.J., said phase II results were published in the New England Journal of Medicine showing the safety and efficacy of letermovir, an oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription